COVID-19: Drug Targets and Potential Treatments
The DOI matches its Crossref record; 243 of the 243 references it cites were found in a registry or an index.
Abstract
Currently, humans are immersed in a pandemic caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which threatens public health worldwide. To date, no drug or vaccine has been approved to treat the severe disease caused by this coronavirus, COVID-19. In this paper, we will focus on the main virus-based and host-based targets that can guide efforts in medicinal chemistry to discover new drugs for this devastating disease. In principle, all CoV enzymes and proteins involved in viral replication and the control of host cellular machineries are potentially druggable targets in the search for therapeutic options for SARS-CoV-2. This Perspective provides an overview of the main targets from a structural point of view, together with reported therapeutic compounds with activity against SARS-CoV-2 and/or other CoVs. Also, the role of innate immune response to coronavirus infection and the related therapeutic options will be presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
Origin and evolution of pathogenic coronaviruses
Cui, J., Li, F., & Shi, Z.-L. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,515
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 5,040
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2223-y · Cited by 4,358
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,440
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
Chan, J. F.-W., Kok, K.-H., Zhu, Z., Chu, H., To, K. K.-W., Yuan, S., & Yuen, K.-Y. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,059
Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020) · Science · doi:10.1126/science.abb3405 · Cited by 2,895
Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05985-9 · Cited by 2,684
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R. A., Stahl, M., Leopoldi, A., Garreta, E., Hurtado del Pozo, C., Prosper, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.004 · Cited by 2,122
Coronavirus infections and immune responses
Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25685 · Cited by 1,946
Hoffmann, M., Kleine-Weber, H., & Pöhlmann, S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.022 · Cited by 1,852
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Li, G., & De Clercq, E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00016-0 · Cited by 1,729
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N. G., & Decroly, E. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104742 · Cited by 1,679
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
Gao, Y., Yan, L., Huang, Y., Liu, F., Zhao, Y., Cao, L., Wang, T., Sun, Q., Ming, Z., Zhang, L., et al. (2020) · Science · doi:10.1126/science.abb7498 · Cited by 1,609
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L. E., Davey, R. T., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,605
Virology, Epidemiology, Pathogenesis, and Control of COVID-19
Jin, Y., Yang, H., Ji, W., Wu, W., Chen, S., Zhang, W., & Duan, G. (2020) · Viruses · doi:10.3390/v12040372 · Cited by 1,603
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells
Wang, K., Chen, W., Zhang, Z., Deng, Y., Lian, J.-Q., Du, P., Wei, D., Zhang, Y., Sun, X.-X., Gong, L., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00426-x · Cited by 1,593
Randall, R. E., & Goodbourn, S. (2008) · Journal of General Virology · doi:10.1099/vir.0.83391-0 · Cited by 1,571
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,571
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic
(2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200220-0772 · Cited by 1,537
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416
Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
Matsuyama, S., Nao, N., Shirato, K., Kawase, M., Saito, S., Takayama, I., Nagata, N., Sekizuka, T., Katoh, H., Kato, F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002589117 · Cited by 1,411
Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein
Belouzard, S., Millet, J. K., Licitra, B. N., & Whittaker, G. R. (2012) · Viruses · doi:10.3390/v4061011 · Cited by 1,368
Xia, S., Liu, M., Wang, C., Xu, W., Lan, Q., Feng, S., Qi, F., Bao, L., Du, L., Liu, S., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0305-x · Cited by 1,343
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Yin, W., Mao, C., Luan, X., Shen, D.-D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., et al. (2020) · Science · doi:10.1126/science.abc1560 · Cited by 1,219
Review of Pharmacological Effects of Glycyrrhiza sp. and its Bioactive Compounds
Asl, M. N., & Hosseinzadeh, H. (2008) · Phytotherapy Research · doi:10.1002/ptr.2362 · Cited by 1,136
COVID-19: combining antiviral and anti-inflammatory treatments
Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30132-8 · Cited by 1,117
Ahmed, S. F., Quadeer, A. A., & McKay, M. R. (2020) · Viruses · doi:10.3390/v12030254 · Cited by 1,116
Lukassen, S., Chua, R. L., Trefzer, T., Kahn, N. C., Schneider, M. A., Muley, T., Winter, H., Meister, M., Veith, C., Boots, A. W., et al. (2020) · The EMBO Journal · doi:10.15252/embj.20105114 · Cited by 1,100
The Coronavirus Nucleocapsid Is a Multifunctional Protein
McBride, R., Van Zyl, M., & Fielding, B. (2014) · Viruses · doi:10.3390/v6082991 · Cited by 942
Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117592 · Cited by 923
Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis
Millet, J. K., & Whittaker, G. R. (2015) · Virus Research · doi:10.1016/j.virusres.2014.11.021 · Cited by 902
Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors
Kirchdoerfer, R. N., & Ward, A. B. (2019) · Nature Communications · doi:10.1038/s41467-019-10280-3 · Cited by 896
Mechanisms and enzymes involved in SARS coronavirus genome expression
Thiel, V., Ivanov, K. A., Putics, Á., Hertzig, T., Schelle, B., Bayer, S., Weißbrich, B., Snijder, E. J., Rabenau, H., Doerr, H. W., et al. (2003) · Journal of General Virology · doi:10.1099/vir.0.19424-0 · Cited by 848
A structural analysis of M protein in coronavirus assembly and morphology
Neuman, B. W., Kiss, G., Kunding, A. H., Bhella, D., Baksh, M. F., Connelly, S., Droese, B., Klaus, J. P., Makino, S., Sawicki, S. G., et al. (2011) · Journal of Structural Biology · doi:10.1016/j.jsb.2010.11.021 · Cited by 841
Morse, J. S., Lalonde, T., Xu, S., & Liu, W. R. (2020) · ChemBioChem · doi:10.1002/cbic.202000047 · Cited by 776
de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J., & Snijder, E. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03011-14 · Cited by 736
Wang, H., Yang, P., Liu, K., Guo, F., Zhang, Y., Zhang, G., & Jiang, C. (2008) · Cell Research · doi:10.1038/cr.2008.15 · Cited by 707
Millet, J. K., & Whittaker, G. R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407087111 · Cited by 698
Kopecky-Bromberg, S. A., Martínez-Sobrido, L., Frieman, M., Baric, R. A., & Palese, P. (2007) · Journal of Virology · doi:10.1128/jvi.01782-06 · Cited by 673
COVID-19: Immunology and treatment options
Felsenstein, S., Herbert, J. A., McNamara, P. S., & Hedrich, C. M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108448 · Cited by 669
From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design
Hilgenfeld, R. (2014) · The FEBS Journal · doi:10.1111/febs.12936 · Cited by 660
Dyall, J., Coleman, C. M., Hart, B. J., Venkataraman, T., Holbrook, M. R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Jahrling, P. B., Laidlaw, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03036-14 · Cited by 660
Coronavirus Spike Proteins in Viral Entry and Pathogenesis
Gallagher, T. M., & Buchmeier, M. J. (2001) · Virology · doi:10.1006/viro.2000.0757 · Cited by 658
Kang, S., Yang, M., Hong, Z., Zhang, L., Huang, Z., Chen, X., He, S., Zhou, Z., Zhou, Z., Chen, Q., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.009 · Cited by 632
Liu, W., Liu, L., Kou, G., Zheng, Y., Ding, Y., Ni, W., Wang, Q., Tan, L., Wu, W., Tang, S., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00461-20 · Cited by 630
Minskaia, E., Hertzig, T., Gorbalenya, A. E., Campanacci, V., Cambillau, C., Canard, B., & Ziebuhr, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508200103 · Cited by 624
Iwata-Yoshikawa, N., Okamura, T., Shimizu, Y., Hasegawa, H., Takeda, M., & Nagata, N. (2019) · Journal of Virology · doi:10.1128/jvi.01815-18 · Cited by 618
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Warren, T. K., Wells, J., Panchal, R. G., Stuthman, K. S., Garza, N. L., Van Tongeren, S. A., Dong, L., Retterer, C. J., Eaton, B. P., Pegoraro, G., et al. (2014) · Nature · doi:10.1038/nature13027 · Cited by 610
Chan, J. F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv392 · Cited by 608
On the use of corticosteroids for 2019-nCoV pneumonia
Shang, L., Zhao, J., Hu, Y., Du, R., & Cao, B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30361-5 · Cited by 604
Subissi, L., Posthuma, C. C., Collet, A., Zevenhoven-Dobbe, J. C., Gorbalenya, A. E., Decroly, E., Snijder, E. J., Canard, B., & Imbert, I. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323705111 · Cited by 595
Human Coronaviruses: A Review of Virus–Host Interactions
Lim, Y., Ng, Y., Tam, J., & Liu, D. (2016) · Diseases · doi:10.3390/diseases4030026 · Cited by 591
Vankadari, N., & Wilce, J. A. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1739565 · Cited by 585
Protease inhibitors targeting coronavirus and filovirus entry
Zhou, Y., Vedantham, P., Lu, K., Agudelo, J., Carrion, R., Nunneley, J. W., Barnard, D., Pöhlmann, S., McKerrow, J. H., Renslo, A. R., et al. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.01.011 · Cited by 583
Zhang, L., Lin, D., Kusov, Y., Nian, Y., Ma, Q., Wang, J., von Brunn, A., Leyssen, P., Lanko, K., Neyts, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01828 · Cited by 568
SARS — beginning to understand a new virus
Stadler, K., Masignani, V., Eickmann, M., Becker, S., Abrignani, S., Klenk, H.-D., & Rappuoli, R. (2003) · Nature Reviews Microbiology · doi:10.1038/nrmicro775 · Cited by 557
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Rossignol, J.-F. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.07.014 · Cited by 556
Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment
Sakurai, Y., Kolokoltsov, A. A., Chen, C.-C., Tidwell, M. W., Bauta, W. E., Klugbauer, N., Grimm, C., Wahl-Schott, C., Biel, M., & Davey, R. A. (2015) · Science · doi:10.1126/science.1258758 · Cited by 555
Sui, J., Li, W., Murakami, A., Tamin, A., Matthews, L. J., Wong, S. K., Moore, M. J., Tallarico, A. S. C., Olurinde, M., Choe, H., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307140101 · Cited by 550
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
Chen, F., Chan, K. H., Jiang, Y., Kao, R. Y. T., Lu, H. T., Fan, K. W., Cheng, V. C. C., Tsui, W. H. W., Hung, I. F. N., & Lee, T. S. W. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.03.003 · Cited by 534
Nieto-Torres, J. L., Verdiá-Báguena, C., Jimenez-Guardeño, J. M., Regla-Nava, J. A., Castaño-Rodriguez, C., Fernandez-Delgado, R., Torres, J., Aguilella, V. M., & Enjuanes, L. (2015) · Virology · doi:10.1016/j.virol.2015.08.010 · Cited by 511
Liu, S., Xiao, G., Chen, Y., He, Y., Niu, J., Escalante, C. R., Xiong, H., Farmar, J., Debnath, A. K., Tien, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15788-7 · Cited by 505
Deng, L., Li, C., Zeng, Q., Liu, X., Li, X., Zhang, H., Hong, Z., & Xia, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.002 · Cited by 505
Siu, K., Yuen, K., Castano‐Rodriguez, C., Ye, Z., Yeung, M., Fung, S., Yuan, S., Chan, C., Yuen, K., Enjuanes, L., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201802418r · Cited by 502
Systematic Investigation of Halogen Bonding in Protein–Ligand Interactions
Hardegger, L. A., Kuhn, B., Spinnler, B., Anselm, L., Ecabert, R., Stihle, M., Gsell, B., Thoma, R., Diez, J., Benz, J., et al. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201006781 · Cited by 492
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV
Lokugamage, K. G., Hage, A., de Vries, M., Valero-Jimenez, A. M., Schindewolf, C., Dittmann, M., Rajsbaum, R., & Menachery, V. D. (2020) · Journal of Virology · doi:10.1128/jvi.01410-20 · Cited by 483
Structural basis and functional analysis of the SARS coronavirus nsp14–nsp10 complex
Ma, Y., Wu, L., Shaw, N., Gao, Y., Wang, J., Sun, Y., Lou, Z., Yan, L., Zhang, R., & Rao, Z. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508686112 · Cited by 482
Exploitation of glycosylation in enveloped virus pathobiology
Watanabe, Y., Bowden, T. A., Wilson, I. A., & Crispin, M. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.05.012 · Cited by 482
Kuba, K., Imai, Y., Ohto-Nakanishi, T., & Penninger, J. M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.06.003 · Cited by 480
Shi, C.-S., Qi, H.-Y., Boularan, C., Huang, N.-N., Abu-Asab, M., Shelhamer, J. H., & Kehrl, J. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303196 · Cited by 473
Kirchdoerfer, R. N., Wang, N., Pallesen, J., Wrapp, D., Turner, H. L., Cottrell, C. A., Corbett, K. S., Graham, B. S., McLellan, J. S., & Ward, A. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-34171-7 · Cited by 466
Cheung, C. Y., Poon, L. L. M., Ng, I. H. Y., Luk, W., Sia, S.-F., Wu, M. H. S., Chan, K.-H., Yuen, K.-Y., Gordon, S., Guan, Y., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7819-7826.2005 · Cited by 461
Shirato, K., Kawase, M., & Matsuyama, S. (2013) · Journal of Virology · doi:10.1128/jvi.01890-13 · Cited by 453
Rapid generation of a mouse model for Middle East respiratory syndrome
Zhao, J., Li, K., Wohlford-Lenane, C., Agnihothram, S. S., Fett, C., Zhao, J., Gale, M. J., Baric, R. S., Enjuanes, L., Gallagher, T., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323279111 · Cited by 452
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques
Falzarano, D., de Wit, E., Rasmussen, A. L., Feldmann, F., Okumura, A., Scott, D. P., Brining, D., Bushmaker, T., Martellaro, C., Baseler, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3362 · Cited by 445
Smith, E. C., Blanc, H., Vignuzzi, M., & Denison, M. R. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003565 · Cited by 444
Mordstein, M., Neugebauer, E., Ditt, V., Jessen, B., Rieger, T., Falcone, V., Sorgeloos, F., Ehl, S., Mayer, D., Kochs, G., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00272-10 · Cited by 443
Konno, Y., Kimura, I., Uriu, K., Fukushi, M., Irie, T., Koyanagi, Y., Sauter, D., Gifford, R. J., Nakagawa, S., & Sato, K. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108185 · Cited by 433
Accessory proteins of SARS-CoV and other coronaviruses
Liu, D. X., Fung, T. S., Chong, K. K.-L., Shukla, A., & Hilgenfeld, R. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.06.013 · Cited by 431
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
Zhu, Z. H., Lu, Z., Xu, T., Chen, C., Yang, G., Zha, T. A., Lu, J., & Xue, Y. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.060 · Cited by 427
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
Du, Y., & Chen, X. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1844 · Cited by 418
CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement
Ulrich, H., & Pillat, M. M. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-09976-7 · Cited by 418
Devaraj, S. G., Wang, N., Chen, Z., Chen, Z., Tseng, M., Barretto, N., Lin, R., Peters, C. J., Tseng, C.-T. K., Baker, S. C., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704870200 · Cited by 411
Kindrachuk, J., Ork, B., Hart, B. J., Mazur, S., Holbrook, M. R., Frieman, M. B., Traynor, D., Johnson, R. F., Dyall, J., Kuhn, J. H., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03659-14 · Cited by 407
Crystal structure of Nsp15 endoribonuclease NendoU from SARS‐CoV ‐2
Kim, Y., Jedrzejczak, R., Maltseva, N. I., Wilamowski, M., Endres, M., Godzik, A., Michalska, K., & Joachimiak, A. (2020) · Protein Science · doi:10.1002/pro.3873 · Cited by 384
TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?
Stopsack, K. H., Mucci, L. A., Antonarakis, E. S., Nelson, P. S., & Kantoff, P. W. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0451 · Cited by 382
Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
Watanabe, Y., Berndsen, Z. T., Raghwani, J., Seabright, G. E., Allen, J. D., Pybus, O. G., McLellan, J. S., Wilson, I. A., Bowden, T. A., Ward, A. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16567-0 · Cited by 379
Race to find COVID-19 treatments accelerates
Kupferschmidt, K., & Cohen, J. (2020) · Science · doi:10.1126/science.367.6485.1412 · Cited by 378
Lindner, H. A., Fotouhi-Ardakani, N., Lytvyn, V., Lachance, P., Sulea, T., & Ménard, R. (2005) · Journal of Virology · doi:10.1128/jvi.79.24.15199-15208.2005 · Cited by 371
Haschke, M., Schuster, M., Poglitsch, M., Loibner, H., Salzberg, M., Bruggisser, M., Penninger, J., & Krähenbühl, S. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0072-7 · Cited by 361
Effective inhibition of MERS-CoV infection by resveratrol
Lin, S.-C., Ho, C.-T., Chuo, W.-H., Li, S., Wang, T. T., & Lin, C.-C. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2253-8 · Cited by 358
Decroly, E., Debarnot, C., Ferron, F., Bouvet, M., Coutard, B., Imbert, I., Gluais, L., Papageorgiou, N., Sharff, A., Bricogne, G., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002059 · Cited by 357
Bertram, S., Dijkman, R., Habjan, M., Heurich, A., Gierer, S., Glowacka, I., Welsch, K., Winkler, M., Schneider, H., Hofmann-Winkler, H., et al. (2013) · Journal of Virology · doi:10.1128/jvi.03372-12 · Cited by 350
Diaz, J. H. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa041 · Cited by 350
Gierer, S., Bertram, S., Kaup, F., Wrensch, F., Heurich, A., Krämer-Kühl, A., Welsch, K., Winkler, M., Meyer, B., Drosten, C., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00128-13 · Cited by 341
Jia, Z., Yan, L., Ren, Z., Wu, L., Wang, J., Guo, J., Zheng, L., Ming, Z., Zhang, L., Lou, Z., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz409 · Cited by 334
Bertram, S., Glowacka, I., Müller, M. A., Lavender, H., Gnirss, K., Nehlmeier, I., Niemeyer, D., He, Y., Simmons, G., Drosten, C., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05300-11 · Cited by 329
Modular organization of SARS coronavirus nucleocapsid protein
Chang, C.-K., Sue, S.-C., Yu, T.-H., Hsieh, C.-M., Tsai, C.-K., Chiang, Y.-C., Lee, S.-J., Hsiao, H.-H., Wu, W.-J., Chang, W.-L., et al. (2006) · Journal of Biomedical Science · doi:10.1007/s11373-005-9035-9 · Cited by 319
The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated production of type I interferon
Wang, C., Chen, T., Zhang, J., Yang, M., Li, N., Xu, X., & Cao, X. (2009) · Nature Immunology · doi:10.1038/ni.1742 · Cited by 317
Castaño-Rodriguez, C., Honrubia, J. M., Gutiérrez-Álvarez, J., DeDiego, M. L., Nieto-Torres, J. L., Jimenez-Guardeño, J. M., Regla-Nava, J. A., Fernandez-Delgado, R., Verdia-Báguena, C., Queralt-Martín, M., et al. (2018) · mBio · doi:10.1128/mbio.02325-17 · Cited by 313
Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism
Park, J.-E., Li, K., Barlan, A., Fehr, A. R., Perlman, S., McCray, P. B., & Gallagher, T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608147113 · Cited by 307
Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
Ghosh, A. K., Brindisi, M., Shahabi, D., Chapman, M. E., & Mesecar, A. D. (2020) · ChemMedChem · doi:10.1002/cmdc.202000223 · Cited by 306
Wösten‐van Asperen, R. M., Lutter, R., Specht, P. A., Moll, G. N., van Woensel, J. B., van der Loos, C. M., van Goor, H., Kamilic, J., Florquin, S., & Bos, A. P. (2011) · The Journal of Pathology · doi:10.1002/path.2987 · Cited by 304
Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era
Behrens, E. M., & Koretzky, G. A. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40071 · Cited by 304
Hu, Y., Li, W., Gao, T., Cui, Y., Jin, Y., Li, P., Ma, Q., Liu, X., & Cao, C. (2017) · Journal of Virology · doi:10.1128/jvi.02143-16 · Cited by 294
Hasan, A., Paray, B. A., Hussain, A., Qadir, F. A., Attar, F., Aziz, F. M., Sharifi, M., Derakhshankhah, H., Rasti, B., Mehrabi, M., et al. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1754293 · Cited by 293
Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Rossignol, J.-F. (2016) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2016.04.001 · Cited by 290
SARS-CoV-2: virus dynamics and host response
Chen, Y., & Li, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30235-8 · Cited by 286
TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections
Shen, L. W., Mao, H. J., Wu, Y. L., Tanaka, Y., & Zhang, W. (2017) · Biochimie · doi:10.1016/j.biochi.2017.07.016 · Cited by 285
Yang, Y., Zhang, L., Geng, H., Deng, Y., Huang, B., Guo, Y., Zhao, Z., & Tan, W. (2013) · Protein & Cell · doi:10.1007/s13238-013-3096-8 · Cited by 277
Function of HAb18G/CD147 in Invasion of Host Cells by Severe Acute Respiratory Syndrome Coronavirus
Chen, Z., Mi, L., Xu, J., Yu, J., Wang, X., Jiang, J., Xing, J., Shang, P., Qian, A., Li, Y., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/427811 · Cited by 277
Siu, K.-L., Kok, K.-H., Ng, M.-H. J., Poon, V. K. M., Yuen, K.-Y., Zheng, B.-J., & Jin, D.-Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.008227 · Cited by 272
Gupta, M. K., Vemula, S., Donde, R., Gouda, G., Behera, L., & Vadde, R. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1751300 · Cited by 270
Haffizulla, J., Hartman, A., Hoppers, M., Resnick, H., Samudrala, S., Ginocchio, C., Bardin, M., & Rossignol, J.-F. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70717-0 · Cited by 251
Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
Lin, M.-H., Moses, D. C., Hsieh, C.-H., Cheng, S.-C., Chen, Y.-H., Sun, C.-Y., & Chou, C.-Y. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2017.12.015 · Cited by 250
Arabi, Y. M., Shalhoub, S., Mandourah, Y., Al-Hameed, F., Al-Omari, A., Al Qasim, E., Jose, J., Alraddadi, B., Almotairi, A., Al Khatib, K., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz544 · Cited by 248
Mechanisms of Host Receptor Adaptation by Severe Acute Respiratory Syndrome Coronavirus
Wu, K., Peng, G., Wilken, M., Geraghty, R. J., & Li, F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.325803 · Cited by 246
PIKfyve Regulation of Endosome‐Linked Pathways
de Lartigue, J., Polson, H., Feldman, M., Shokat, K., Tooze, S. A., Urbé, S., & Clague, M. J. (2009) · Traffic · doi:10.1111/j.1600-0854.2009.00915.x · Cited by 240
Nutho, B., Mahalapbutr, P., Hengphasatporn, K., Pattaranggoon, N. C., Simanon, N., Shigeta, Y., Hannongbua, S., & Rungrotmongkol, T. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00160 · Cited by 238
Lu, X., Pan, J., Tao, J., & Guo, D. (2011) · Virus Genes · doi:10.1007/s11262-010-0544-x · Cited by 235
SARS coronavirus and innate immunity
Frieman, M., Heise, M., & Baric, R. (2008) · Virus Research · doi:10.1016/j.virusres.2007.03.015 · Cited by 235
Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia
Zhou, W., Liu, Y., Tian, D., Wang, C., Wang, S., Cheng, J., Hu, M., Fang, M., & Gao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0127-9 · Cited by 234
MERS-CoV papain-like protease has deISGylating and deubiquitinating activities
Mielech, A. M., Kilianski, A., Baez-Santos, Y. M., Mesecar, A. D., & Baker, S. C. (2014) · Virology · doi:10.1016/j.virol.2013.11.040 · Cited by 231
Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication
Kindler, E., Gil-Cruz, C., Spanier, J., Li, Y., Wilhelm, J., Rabouw, H. H., Züst, R., Hwang, M., V’kovski, P., Stalder, H., et al. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006195 · Cited by 230
Dosch, S. F., Mahajan, S. D., & Collins, A. R. (2009) · Virus Research · doi:10.1016/j.virusres.2009.01.005 · Cited by 228
Bekerman, E., Neveu, G., Shulla, A., Brannan, J., Pu, S.-Y., Wang, S., Xiao, F., Barouch-Bentov, R., Bakken, R. R., Mateo, R., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89857 · Cited by 226
Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry
Shirato, K., Kawase, M., & Matsuyama, S. (2018) · Virology · doi:10.1016/j.virol.2017.11.012 · Cited by 225
Morgenstern, B., Michaelis, M., Baer, P. C., Doerr, H. W., & Cinatl, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.128 · Cited by 214
Hart, B. J., Dyall, J., Postnikova, E., Zhou, H., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Frieman, M. B., Holbrook, M. R., Jahrling, P. B., et al. (2014) · Journal of General Virology · doi:10.1099/vir.0.061911-0 · Cited by 211
Ma-Lauer, Y., Carbajo-Lozoya, J., Hein, M. Y., Müller, M. A., Deng, W., Lei, J., Meyer, B., Kusov, Y., von Brunn, B., Bairad, D. R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603435113 · Cited by 210
Smith, M., & Smith, J. C. (2020) · ChemRxiv · doi:10.26434/chemrxiv.11871402.v4 · Cited by 206
Cell Pyroptosis, a Potential Pathogenic Mechanism of 2019-nCoV Infection
Yang, M. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3527420 · Cited by 200
Rabouw, H. H., Langereis, M. A., Knaap, R. C. M., Dalebout, T. J., Canton, J., Sola, I., Enjuanes, L., Bredenbeek, P. J., Kikkert, M., de Groot, R. J., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005982 · Cited by 192
V'kovski, P., Gerber, M., Kelly, J., Pfaender, S., Ebert, N., Braga Lagache, S., Simillion, C., Portmann, J., Stalder, H., Gaschen, V., et al. (2019) · eLife · doi:10.7554/elife.42037 · Cited by 186
Xiao, L., Sakagami, H., & Miwa, N. (2020) · Viruses · doi:10.3390/v12050491 · Cited by 186
Adedeji, A. O., Severson, W., Jonsson, C., Singh, K., Weiss, S. R., & Sarafianos, S. G. (2013) · Journal of Virology · doi:10.1128/jvi.00998-13 · Cited by 183
McBride, C. E., Li, J., & Machamer, C. E. (2007) · Journal of Virology · doi:10.1128/jvi.02146-06 · Cited by 182
Shirogane, Y., Takeda, M., Iwasaki, M., Ishiguro, N., Takeuchi, H., Nakatsu, Y., Tahara, M., Kikuta, H., & Yanagi, Y. (2008) · Journal of Virology · doi:10.1128/jvi.00676-08 · Cited by 180
Tanner, J. A., Zheng, B.-J., Zhou, J., Watt, R. M., Jiang, J.-Q., Wong, K.-L., Lin, Y.-P., Lu, L.-Y., He, M.-L., Kung, H.-F., et al. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.01.006 · Cited by 176
Potential antivirals and antiviral strategies against SARS coronavirus infections
De Clercq, E. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.2.291 · Cited by 176
Li, S.-W., Wang, C.-Y., Jou, Y.-J., Huang, S.-H., Hsiao, L.-H., Wan, L., Lin, Y.-J., Kung, S.-H., & Lin, C.-W. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050678 · Cited by 176
PIKfyve: Partners, significance, debates and paradoxes
Shisheva, A. (2008) · Cell Biology International · doi:10.1016/j.cellbi.2008.01.006 · Cited by 175
Glycyrrhizin inhibits influenza A virus uptake into the cell
Wolkerstorfer, A., Kurz, H., Bachhofner, N., & Szolar, O. H. J. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.04.012 · Cited by 172
Lee, T.-W., Cherney, M. M., Huitema, C., Liu, J., James, K. E., Powers, J. C., Eltis, L. D., & James, M. N. G. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.09.004 · Cited by 170
Dynamics of phosphoinositide conversion in clathrin-mediated endocytic traffic
He, K., Marsland, R., III, Upadhyayula, S., Song, E., Dang, S., Capraro, B. R., Wang, W., Skillern, W., Gaudin, R., Ma, M., et al. (2017) · Nature · doi:10.1038/nature25146 · Cited by 167
Yang, X., Chen, X., Bian, G., Tu, J., Xing, Y., Wang, Y., & Chen, Z. (2013) · Journal of General Virology · doi:10.1099/vir.0.059014-0 · Cited by 165
Michaelis, M., Geiler, J., Naczk, P., Sithisarn, P., Leutz, A., Doerr, H. W., & Cinatl, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019705 · Cited by 164
Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection
Padmanabhan, P., Desikan, R., & Dixit, N. M. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008461 · Cited by 160
Bécares, M., Pascual‐Iglesias, A., Nogales, A., Sola, I., Enjuanes, L., & Zúñiga, S. (2016) · Journal of Virology · doi:10.1128/jvi.03259-15 · Cited by 147
Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
Zhou, Y., Yang, Y., Huang, J., Jiang, S., & Du, L. (2019) · Viruses · doi:10.3390/v11010060 · Cited by 143
Family-wide Structural Analysis of Human Numb-Associated Protein Kinases
Sorrell, F. J., Szklarz, M., Abdul Azeez, K. R., Elkins, J. M., & Knapp, S. (2016) · Structure · doi:10.1016/j.str.2015.12.015 · Cited by 141
Adedeji, A. O., Singh, K., Calcaterra, N. E., DeDiego, M. L., Enjuanes, L., Weiss, S. R., & Sarafianos, S. G. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00957-12 · Cited by 137
Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer
Cao, L., Pauthner, M. G., Andrabi, R., Rantalainen, K. I., Berndsen, Z. T., Diedrich, J. K., Menis, S., Sok, D., Bastidas, R. B., Park, S. K. R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06121-4 · Cited by 134
Yu, I.-M., Oldham, M. L., Zhang, J., & Chen, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602107200 · Cited by 132
Structural mechanisms of phospholipid activation of the human TPC2 channel
She, J., Zeng, W., Guo, J., Chen, Q., Bai, X., & Jiang, Y. (2019) · eLife · doi:10.7554/elife.45222 · Cited by 132
Hardegger, L. A., Kuhn, B., Spinnler, B., Anselm, L., Ecabert, R., Stihle, M., Gsell, B., Thoma, R., Diez, J., Benz, J., et al. (2011) · ChemMedChem · doi:10.1002/cmdc.201100353 · Cited by 131
The life cycle of SARS coronavirus in Vero E6 cells
Qinfen, Z., Cui, J., Huang, X., Huanying, Z., Jicheng, H., Fang, L., Li, K., & Jingqiang, Z. (2004) · Journal of Medical Virology · doi:10.1002/jmv.20095 · Cited by 131
Du, L., Tai, W., Yang, Y., Zhao, G., Zhu, Q., Sun, S., Liu, C., Tao, X., Tseng, C.-T. K., Perlman, S. M., et al. (2016) · Nature Communications · doi:10.1038/ncomms13473 · Cited by 124
Barton, C. R., Kouokam, J. C., Lasnik, A. B., Foreman, O., Cambon, A. C., Brock, G. N., Montefiori, D. C., Vojdani, F., McCormick, A. A., O’Keefe, B. R., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01407-13 · Cited by 123
COVID-19: Therapeutics and Their Toxicities
Chary, M. A., Barbuto, A. F., Izadmehr, S., Hayes, B. D., & Burns, M. M. (2020) · Journal of Medical Toxicology · doi:10.1007/s13181-020-00777-5 · Cited by 122
Adedeji, A. O., Singh, K., Kassim, A., Coleman, C. M., Elliott, R., Weiss, S. R., Frieman, M. B., & Sarafianos, S. G. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02994-14 · Cited by 120
Nelson, E. A., Dyall, J., Hoenen, T., Barnes, A. B., Zhou, H., Liang, J. Y., Michelotti, J. M., Dewey, W. H., DeWald, L. E., Bennett, R. S., et al. (2017) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0005540 · Cited by 116
Expression, purification, and characterization of SARS coronavirus RNA polymerase
Cheng, A., Zhang, W., Xie, Y., Jiang, W., Arnold, E., Sarafianos, S. G., & Ding, J. (2005) · Virology · doi:10.1016/j.virol.2005.02.017 · Cited by 114
Chang, C., Lo, S.-C., Wang, Y., & Hou, M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.11.015 · Cited by 113
Tissue Angiotensin II Generating System by Angiotensin-Converting Enzyme and Chymase
Miyazaki, M., & Takai, S. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.cpj06008x · Cited by 112
Dong, S., Sun, J., Mao, Z., Wang, L., Lu, Y.-L., & Li, J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25768 · Cited by 112
Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment
Pu, S., Xiao, F., Schor, S., Bekerman, E., Zanini, F., Barouch‐Bentov, R., Nagamine, C. M., & Einav, S. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.05.001 · Cited by 110
Lin, S., Lin, S., Hsu, J.-N., Chang, C., Chien, C., Wang, Y., Wu, H., Jeng, U., Kehn‐Hall, K., & Hou, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01913 · Cited by 109
Yang, W., Ru, Y., Ren, J., Bai, J., Wei, J., Fu, S., Liu, X., Li, D., & Zheng, H. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2178-9 · Cited by 107
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
Praveen, D., Puvvada, R. C., & Aanandhi, M. V. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105967 · Cited by 103
Kuri, T., Eriksson, K. K., Putics, A., Züst, R., Snijder, E. J., Davidson, A. D., Siddell, S. G., Thiel, V., Ziebuhr, J., & Weber, F. (2011) · Journal of General Virology · doi:10.1099/vir.0.031856-0 · Cited by 101
Li, N., Zhao, D., Kirschbaum, M. H., Zhang, C., Lin, C.-L. V., Todorov, I., KANDEEL, F. R., Forman, S. J., & Zeng, D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712051105 · Cited by 94
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Structural insights into SARS-CoV-2 proteins
Arya, R., Kumari, S., Pandey, B., Mistry, H., Bihani, S. C., Das, A., Prashar, V., Gupta, G. D., Panicker, L., & Kumar, M. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.11.024 · Cited by 348
Structural biology of SARS-CoV-2: open the door for novel therapies
Yan, W., Zheng, Y., Zeng, X., He, B., & Cheng, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00884-5 · Cited by 291
Molecular Docking: Principles, Advances, and Its Applications in Drug Discovery
Muhammed, M. T., & Aki-Yalcin, E. (2024) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220922103109 · Cited by 267
Barh, D., Tiwari, S., Weener, M. E., Azevedo, V., Góes-Neto, A., Gromiha, M. M., & Ghosh, P. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.104051 · Cited by 90
Metadata
- Authors
- Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. Á., Urquiza, J., Ramírez, D., Alonso, C., Campillo, N. E., & Martinez, A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-06-08
- Volume
- 63
- Issue
- 21
- Pages
- 12359-12386
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3033737840
- Cited by
- 445
- References
- 243
- FWCI
- 10.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.